Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer

Venesmaa, Pekka; Lehtovirta, Pentti; Stenman, Ulf Håkan; Leminen, Arto; Forss, M.; Ylikorkala, Olavi

doi:10.1038/bjc.1994.471

Cited by 27 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strong prognostic value of TATI expression in ovarian cancer tissue appears to explain our earlier findings showing that serum TATI predicts adverse survival in epithelial ovarian cancer (3,30,31). Serum TATI correlated with prognosis in advanced ovarian cancer also in this study, but an elevated serum concentration of trypsin-2-API was a prognostic factor both among all patients and those with advanced disease.…”

Section: Discussionsupporting

confidence: 38%

See 1 more Smart Citation

Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer

Paju¹,

Vartiainen

Haglund

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose:The purpose is to study the prognostic significance of tissue expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor (TATI) and serum concentration of trypsinogen-2, trypsin-2-API (complex of trypsin-2 with ␣-1-proteinase inhibitor), and TATI in epithelial ovarian cancer.Experimental Design: Expression of trypsinogen-1, trypsinogen-2, and TATI was determined by immunohistochemistry with monoclonal antibodies in tissue sections of tumors from 119 patients with untreated primary epithelial ovarian cancer. Preoperative serum concentrations of trypsinogen-2, trypsin-2-API and TATI were analyzed using specific immunoassays.Results: Fifty-four percent of the tumors expressed trypsinogen-1, 45% expressed trypsinogen-2, and 30% expressed TATI. In patients with stage III and IV disease, TATI tissue expression (P ‫؍‬ 0.002) and elevated TATI concentration in serum (P ‫؍‬ 0.048) were associated with adverse cancer-specific and progression-free survival in univariate analysis. In multivariate analysis, TATI tissue expression (P ‫؍‬ 0.005), tumor grade (P ‫؍‬ 0.0001), histological type (P ‫؍‬ 0.02), and stage (P ‫؍‬ 0.0005) were independent prognostic factors for adverse cancer-specific survival and TATI tissue expression (P ‫؍‬ 0.006) and grade (P ‫؍‬ 0.0003) for progression-free survival. In multivariate analysis of all patients and those with advanced disease, serum trypsin-2-API concentration was an adverse prognostic factor for cancer-specific and progression-free survival, and it was independent of stage and histological type of the tumor (P < 0.01).Conclusions: Tissue expression of TATI and an elevated preoperative serum concentration of trypsin-2-API are strong independent prognostic factors in advanced epithelial ovarian cancer. These results suggest that trypsin expression plays a role in the progression of ovarian cancer. TATI and trypsin-2-API are of potential use as an aid for stratification of randomized studies and for selecting treatment strategies.

show abstract

Section: Discussionsupporting

confidence: 38%

“…TATI is expressed together with trypsin in several tumors and cancer cell lines (29), and elevated serum concentrations are common in several malignant diseases (29). TATI is a useful serum marker for diagnosis of mucinous ovarian cancer and a prognostic factor for ovarian (30,31) and renal cell cancer (32).…”

Section: Introductionmentioning

confidence: 99%

Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer

Paju¹,

Vartiainen

Haglund

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…The predictive value of pretreatment CA-125 a levels for prognosis is controversial. While some studies did not find preoperative CA-125 levels to be an independent prognostic factor (19)(20)(21), others reported that it could identify poor prognostic subgroups, independent of stage (22,23). However, changes in CA-125 levels can also correlate with regression, stability, and progression of the disease in 87% to 94% of instances (12).…”

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Kobayashi

Ueda

Matsuzaki

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

101

View full text Add to dashboard Cite

Serum tumor markers have a major role in the screening, diagnosis, and monitoring of most of the gynecologic cancers. Ovarian cancer is one of the deadliest of the group because it is so frequently asymptomatic until it has advanced to an untreatable stage. Even serum cancer antigen-125 (CA-125), clinically one of the most reliable serum markers for ovarian cancer, is elevated in only half of early-stage still-treatable tumors. Because of the very low prevalence of ovarian cancer in the general population, at present, there is no cost-effective imaging or simple microscopic screening test for ovarian cancer as there is for breast and cervical cancers. However, recent proteomics and nucleic acid-based analyses have shown great promise for the discovery of new and more useful serum biomarkers, which cumulatively might provide such a screening tool. In this review, we will discuss both the currently used serum tumor markers for screening, diagnosis, monitoring of ovarian cancer, and the novel biomarkers that are now under investigation and validation.

show abstract

“…TATI has been shown to be prognostic factor in ovarian cancer (Venesmaa et al, 1994), bladder cancer (Kelloniemi et al, 2003), hepatocellular carcinoma (Lee et al, 2007), and renal cell carcinoma (Paju et al, 2001a). The function of TATI in cancer is thought to be the same as in the pancreas, i.e.…”

Section: Psti/tati In Cancermentioning

confidence: 99%

“…However, in ovarian (Paju et al, 2004, Venesmaa et al, 1994, Venesmaa et al, 1998, bladder (Kelloniemi et al, 2003), prostate (Paju et al, 2007) and renal cell cancers (Paju et al, 2001a) an increased serum level of TATI is a marker of poor prognosis. In a previous report, PSTI/TATI expression correlated, in intestinal type of gastric tumours, with advanced stage tumours as well as nodal involvement (Higashiyama et al, 1990a).…”

Section: Immunoreactive Tati In Cancermentioning

confidence: 99%

Human trypsinogens in the pancreas and in cancer

Itkonen

2010

Scandinavian Journal of Clinical and Laboratory Investigation

View full text Add to dashboard Cite

show abstract

Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer

Abstract: Summary We have evaluated the prognostic value of tumour-associated trypsin inhibitor (TATI)

Cited by 27 publications

References 16 publications

Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer

Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-Associated Trypsin Inhibitor in Ovarian Cancer

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Human trypsinogens in the pancreas and in cancer

Contact Info

Product

Resources

About